
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
Key Takeaways
- FDA labeling for liso-cel in LBCL no longer includes a limitation of use excluding patients with PCNSL.
- The approved LBCL subtypes span DLBCL NOS (including transformed disease), high-grade B-cell lymphoma, PMBCL, and grade 3B follicular lymphoma.
The FDA removed the PCNSL limitation of use from the liso-cel label in LBCL, making it the second CAR T-cell therapy with this update.
The FDA has approved a label update for the indication for lisocabtagene maraleucel (Breyanzi; liso-cel) in large B-cell lymphoma (LBCL), removing the limitations of use for the CAR T-cell therapy in patients with primary central nervous system lymphoma (PCNSL).1
Liso-cel is approved for adult patients with LBCL, including diffuse LBCL (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have:
- refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or
- refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age; or
- relapsed or refractory disease after 2 or more lines of systemic therapy
Liso-cel is now the second CAR T-cell therapy to have its limitations of use removed for patients with PCNSL, following
How was liso-cel evaluated in second-line LBCL?
The indication for patients with refractory disease or relapse within 12 months of first-line chemoimmunotherapy is supported by the randomized, open-label, multicenter phase 3 TRANSFORM trial (NCT03575351).1
The trial enrolled patients who were candidates for HSCT, and 184 patients were randomly assigned 1:1 to receive liso-cel (n = 92) or standard therapy (n = 92), which comprised 3 cycles of chemoimmunotherapy followed by high-dose therapy and autologous HSCT in patients who achieved a complete response (CR) or partial response. Liso-cel was given at a target dose of 100 × 10⁶ CAR-positive viable T cells following lymphodepletion with fludarabine at 30 mg/m² per day and cyclophosphamide at 300 mg/m² per day for 3 days.
The primary end point was event-free survival (EFS) by independent review committee assessment.
Liso-cel produced a median EFS of 10.1 months (95% CI, 6.1-not reached) vs 2.3 months (95% CI, 2.2-4.3) with standard therapy (HR, 0.34; 95% CI, 0.22-0.52; one-sided P < .0001). The CR rates were 66% (95% CI, 56%-76%) vs 39% (95% CI, 29%-50%), respectively (P < .0001), and the respective median progression-free survivals were 14.8 months (95% CI, 6.6-not reached) vs 5.7 months (95% CI, 3.9-9.4; HR, 0.41; 95% CI, 0.25-0.66; P = .0001). Overall survival did not reach statistical significance at the interim analysis.
How was liso-cel evaluated in transplant-ineligible patients?
The indication for patients who are not eligible for HSCT after first-line chemoimmunotherapy is supported by the single-arm, open-label, multicenter phase 2 PILOT trial (NCT03483103). Patients were required to meet at least 1 criterion for transplant ineligibility, such as age of 70 years or older, an ECOG performance status of 2, or impaired pulmonary, cardiac, renal, or hepatic function. Patients received a planned dose of 100 × 10⁶ CAR-positive viable T cells following the same lymphodepletion regimen, and efficacy was based on CR rate by an independent review committee per Lugano 2014 criteria.
Among patients who received liso-cel (n = 61), the overall response rate (ORR) was 80% (95% CI, 68%-89%), including a CR rate of 54% (95% CI, 41%-67%). The median time to CR was 1 month (range, 0.8-6.9). The median duration of response (DOR) was 11.2 months (95% CI, 5.1-not reached) among all responders and was not reached (95% CI, 11.2-not reached) among patients who achieved a CR. Among all leukapheresed patients (n = 74), the ORR was 68% (95% CI, 56%-78%).
How was liso-cel evaluated in third-line and later LBCL?
The indication for patients with relapsed or refractory LBCL after 2 or more lines of systemic therapy is supported by the LBCL cohort of the open-label, multicenter, single-arm phase 1 TRANSCEND NHL 001 trial (NCT02631044). The trial allowed enrollment of patients with prior HSCT and secondary central nervous system (CNS) lymphoma involvement. Patients received liso-cel within a dose range of 50 to 110 × 10⁶ CAR-positive viable T cells following lymphodepletion with fludarabine and cyclophosphamide, in both inpatient and outpatient settings.
Among efficacy-evaluable patients (n = 192), the ORR was 73% (95% CI, 67%-80%), and the CR rate was 54% (95% CI, 47%-61%). The median DOR was 16.7 months (95% CI, 5.3-not reached) and was not reached (95% CI, 16.7-not reached) among patients with a best response of CR. The median time to first response was 1.0 months (range, 0.7-8.9).
What is the safety profile of liso-cel in LBCL?
The prescribing information for liso-cel carries a boxed warning for cytokine release syndrome (CRS), neurologic toxicities, and T-cell malignancies. Any-grade CRS occurred in 49% of patients in TRANSFORM (n = 89), 39% in PILOT (n = 61), and 46% in the TRANSCEND NHL 001 LBCL cohort (n = 268); grade 3 or higher CRS occurred in 1.1%, 1.6%, and 4.1%, respectively. Grade 3 or higher encephalopathy was reported in 4.9% of patients in PILOT and 9% of patients in TRANSCEND NHL 001.
Serious adverse effects (AEs) occurred in 38% of patients in TRANSFORM, 33% in PILOT, and 46% in TRANSCEND NHL 001, and fatal AEs occurred in 4% of patients in TRANSCEND NHL 001.1The most common AEs (≥20%) in TRANSFORM were fever, musculoskeletal pain, headache, fatigue, nausea, constipation, and dizziness. In PILOT, the most common AEs were fatigue, fever, nausea, encephalopathy, hypotension, musculoskeletal pain, and edema.
References
- Breyanzi. Prescribing information. Bristol Myers Squibb; 2026. Accessed November 17, 2026. https://packageinserts.bms.com/pi/pi_breyanzi.pdf
- FDA approves label update for Kite’s Yescarta for relapsed/refractory primary central nervous system lymphoma. News release. Kite. February 6, 2026. Accessed November 17, 2026. https://www.kitepharma.com/news/press-releases/2026/2/fda-approves-label-update-for-kites-yescarta-for-relapsedrefractory-primary-central-nervous-system-lymphoma
Related to this article








